Invenomic Capital Management LP Acquires 1,375,647 Shares of Acadia Healthcare Company, Inc. $ACHC

Invenomic Capital Management LP grew its holdings in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 71.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,312,043 shares of the company’s stock after purchasing an additional 1,375,647 shares during the quarter. Acadia Healthcare makes up approximately 2.2% of Invenomic Capital Management LP’s holdings, making the stock its 6th biggest holding. Invenomic Capital Management LP’s holdings in Acadia Healthcare were worth $46,998,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Capitolis Liquid Global Markets LLC bought a new stake in shares of Acadia Healthcare during the fourth quarter worth approximately $8,954,000. Boothbay Fund Management LLC grew its holdings in Acadia Healthcare by 61.6% during the 4th quarter. Boothbay Fund Management LLC now owns 71,154 shares of the company’s stock worth $1,010,000 after acquiring an additional 27,134 shares during the period. Guggenheim Capital LLC grew its holdings in Acadia Healthcare by 191.2% during the 4th quarter. Guggenheim Capital LLC now owns 63,693 shares of the company’s stock worth $904,000 after acquiring an additional 41,824 shares during the period. Schonfeld Strategic Advisors LLC raised its position in shares of Acadia Healthcare by 78.7% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 103,471 shares of the company’s stock valued at $1,468,000 after acquiring an additional 45,572 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in shares of Acadia Healthcare by 72.8% in the 4th quarter. AQR Capital Management LLC now owns 272,670 shares of the company’s stock valued at $3,869,000 after purchasing an additional 114,868 shares during the period.

Acadia Healthcare Trading Down 6.0%

NASDAQ:ACHC opened at $23.50 on Thursday. The company has a debt-to-equity ratio of 1.27, a current ratio of 1.71 and a quick ratio of 1.71. The business’s 50-day simple moving average is $25.53 and its 200-day simple moving average is $20.23. Acadia Healthcare Company, Inc. has a fifty-two week low of $11.43 and a fifty-two week high of $30.20. The stock has a market capitalization of $2.16 billion, a PE ratio of -1.92, a price-to-earnings-growth ratio of 8.34 and a beta of 0.69.

Acadia Healthcare (NASDAQ:ACHC) last posted its earnings results on Wednesday, April 29th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.09. The business had revenue of $828.80 million during the quarter, compared to analysts’ expectations of $823.51 million. Acadia Healthcare had a positive return on equity of 7.09% and a negative net margin of 32.84%.Acadia Healthcare’s revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.40 EPS. Acadia Healthcare has set its Q2 2026 guidance at 0.300-0.400 EPS. Sell-side analysts expect that Acadia Healthcare Company, Inc. will post 1.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ACHC shares. Jefferies Financial Group upgraded Acadia Healthcare from a “hold” rating to a “buy” rating and raised their price target for the stock from $24.50 to $30.00 in a research report on Wednesday, June 3rd. Leerink Partners increased their target price on Acadia Healthcare from $14.00 to $22.00 and gave the company a “market perform” rating in a research note on Thursday, February 26th. Royal Bank Of Canada raised their target price on Acadia Healthcare from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Monday, May 4th. TD Cowen upped their price target on Acadia Healthcare from $24.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Finally, Guggenheim lifted their price objective on shares of Acadia Healthcare from $26.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $26.85.

Acadia Healthcare Profile

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.